VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc.
(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse
pipeline of novel, multifunctional biotherapeutics to improve the standard of
care for difficult-to-treat diseases, today announced that management will
participate in the following upcoming investor conferences:

  * Bank of America Securities Health Care Conference: Zymeworks' management
    will participate in one-on-one meetings on May 15(th) in Las Vegas, NV.
  * J.P. Morgan Biotech Virtual Call Series: Zymeworks' management will
    participate in a virtual fireside chat on May 15(th) at 10:00 am Pacific
    Time.

About Zymeworks Inc.
Zymeworks is a global biotechnology company committed to the discovery,
development, and commercialization of novel, multifunctional biotherapeutics.
Zymeworks' mission is to make a meaningful difference in the lives of people
impacted by difficult-to-treat cancers and other diseases. The Company's
complementary therapeutic platforms and fully integrated drug development engine
provide the flexibility and compatibility to precisely engineer and develop
highly differentiated antibody-based therapeutic candidates. Zymeworks
engineered and developed zanidatamab, a HER2-targeted bispecific antibody using
the Company's proprietary Azymetric(TM) technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals
Ireland Limited (Jazz), granting each exclusive rights to develop and
commercialize zanidatamab in different territories. Zanidatamab is currently
being evaluated in multiple global clinical trials as a potential best-in-class
treatment for patients with HER2-expressing cancers. A Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking
accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a
treatment for previously-treated, unresectable, locally advanced, or metastatic
HER2-positive biliary tract cancer (BTC) has been submitted. If approved,
zanidatamab would be the first HER2-targeted treatment specifically approved for
BTC in the U.S. Zymeworks is rapidly advancing a deep pipeline of product
candidates based on its experience and capabilities in both antibody-drug
conjugates and multispecific antibody therapeutics across multiple novel targets
in indications that represent areas of significant unmet medical need. In
addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have
been further leveraged through strategic partnerships with global
biopharmaceutical companies. For information about Zymeworks, visit
www.zymeworks.com (https://www.zymeworks.com/) and follow @ZymeworksInc
(https://twitter.com/ZymeworksInc) on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com (mailto:ir@zymeworks.com)?
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com (mailto:media@zymeworks.com)
Â